Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | DNMT3A loss FLT3 exon 14 ins TET2 loss |
Gene Variant Detail |
DNMT3A loss (loss of function) |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
DNMT3A loss FLT3 exon 14 ins TET2 loss | acute myeloid leukemia | sensitive | Olaparib + Quizartinib | Preclinical - Cell culture | Actionable | In a preclinical study, the combination of Lynparza (olaparib) and Vanflyta (quizartinib) decreased colony formation in mouse acute myeloid leukemia cells harboring a FLT3-ITD mutation and TET2 and DNMT3A loss in culture (PMID: 34215619). | 34215619 | |
DNMT3A loss FLT3 exon 14 ins TET2 loss | acute myeloid leukemia | sensitive | Doxorubicin + Olaparib + Quizartinib | Preclinical - Cell culture | Actionable | In a preclinical study, the combination of Lynparza (olaparib), Adriamycin (doxorubicin), and Vanflyta (quizartinib) increased DNA double-strand breaks and decreased colony formation in mouse acute myeloid leukemia cells harboring a FLT3-ITD mutation and TET2 and DNMT3A loss in culture (PMID: 34215619). | 34215619 | |
DNMT3A loss FLT3 exon 14 ins TET2 loss | acute myeloid leukemia | sensitive | Quizartinib + Talazoparib | Preclinical - Cell culture | Actionable | In a preclinical study, the combination of Vanflyta (quizartinib) and Talzenna (talazoparib) decreased colony formation in mouse acute myeloid leukemia cells harboring a FLT3-ITD mutation and TET2 and DNMT3A loss in culture (PMID: 34215619). | 34215619 |